With China CNS Plans, SK Biopharm Completes Strategy For Key Markets

Raises $180M, Largest Series A In China Pharma Industry In 2021

 
• By Jung Won Shin

SK Biopharmaceuticals advances into the Greater China market via a CNS focused Chinese company with China’s 6 Dimensions Capital, backed by a large series A financing. It has also licensed its CNS therapy pipeline to the new Chinese operation.

SK Biopharm Sets Up New Pharma In China
SK Biopharm Licenses Out 6 CNS Pipelines To Newly Established Ignis • Source: SK Biopharmaceuticals

More from Business

More from Scrip